SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Satchel Paige — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSatchel Paige
Date of birth1906-07-07
IdentifiersMRN HR-ML047-SYN-TD; SSN (made up) 000-47-3381
Document date1979-07-28
AuthorDelphine Whitaker-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review on the day of the pulmonology consultation. [S]

History of Present Illness

Mr. Paige returns two weeks after intake and was seen this morning by Dr. Lindqvist-Bello of pulmonology, who did spirometry before and after albuterol, an arterial blood gas and a six-minute walk. He uses his albuterol once or twice a day, mostly before walking to the store, with the spacer. He is still breathless after one flight of stairs or a block on the level and coughs up a little clear sputum each morning. He has had no flare-ups in the past year. He takes atorvastatin each evening without muscle aches. He asked to see his breathing numbers and how they were worked out, and said he had read that lung tests used to be scored differently for Black patients; Dr. Lindqvist-Bello went through the results with him. [S]

ElementDetail
SpirometryPost-bronchodilator FEV1 2.02 L, FVC 3.48 L, FEV1/FVC 0.58; FEV1 61% predicted (GLI Global)
Blood gaspH 7.42, PaCO2 40, PaO2 70 mm Hg on room air
Six-minute walk360 m; lowest saturation 90 percent
SymptomsCAT 18; mMRC 2
ExacerbationsNone in the past year

Review of Systems

SystemResultFinding
RespiratoryPositiveBreathless after a block; morning cough with a little clear sputum; no wheeze at rest or hemoptysis
CardiovascularNegativeNo chest pain, palpitations, orthopnea or ankle swelling
MusculoskeletalNegativeNo muscle aches on atorvastatin

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessnessTwo inhalations with a spacer every 4 hours as neededRespiratory tract route1979-07-14activeS
Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a dayOne inhalation each morning; a strong, deep breath inRespiratory tract route1979-07-28activeS
Atorvastatin 20 mg tablet once a dayOne tablet each eveningOral route1979-07-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1979-07-28Body height191cmS
1979-07-28Body weight82.4kgS
1979-07-28Body mass index (BMI) [Ratio]22.6kg/m2S
1979-07-28Systolic blood pressure132mm[Hg]S
1979-07-28Diastolic blood pressure80mm[Hg]S
1979-07-28Heart rate82/minS
1979-07-28Respiratory rate18/minS
1979-07-28Body temperature36.6CelS
1979-07-28Oxygen saturation in Arterial blood by Pulse oximetry94%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1979-07-28FEV1 --pre bronchodilation1.92LLower limit of normal, GLI Global (race-neutral) for age, sex and heightLowS
1979-07-28FEV1 --post bronchodilation2.02LLower limit of normal, GLI Global (race-neutral)LowS
1979-07-28Forced vital capacity [Volume] Respiratory system --post bronchodilation3.48LLower limit of normal, GLI Global (race-neutral)NormalS
1979-07-28FEV1/FVC --post bronchodilation0.58{ratio}GOLD fixed ratio 0.70; post-bronchodilator ratio below 0.70 confirms airflow obstruction (GLI Global lower limit of normal about 0.62)LowS
1979-07-28FEV1 measured/predicted61%GOLD grade 1 at 80% or more, grade 2 at 50 to 79%LowS
1979-07-28pH of Arterial blood7.42[pH]7.35-7.45 [pH]NormalS
1979-07-28Carbon dioxide [Partial pressure] in Arterial blood40mm[Hg]35-45 mmHgNormalS
1979-07-28Oxygen [Partial pressure] in Arterial blood70mm[Hg]Long-term oxygen threshold: 55 mm Hg or less (60 or less with cor pulmonale or polycythemia)LowS
1979-07-28Six minute walk test360mPredicted about 520 m for his age, sex and height; lower limit about 400 mLowS

Physical Exam

Vital signs recorded on 1979-07-28; see the Vital Signs section. [S]

SystemFinding
GeneralTall and lean; talks in full sentences; blood pressure 132/80, pulse 82, oxygen saturation 94 percent on room air
RespiratoryBarrel-shaped chest; reduced breath sounds throughout; prolonged expiration; no wheeze or crackles
CardiovascularRegular rhythm; heart sounds soft; no edema
Inhaler techniqueAlbuterol with spacer correct; dry powder inhaler technique taught with a placebo device, with a strong, deep breath in, and repeated back correctly

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion for about two years, now after one flight of stairs or a block on the level (mMRC 2), with a morning cough and a little clear sputum most days; no chest pain, ankle swelling, orthopnea, wheeze at rest or weight loss; a former smoker of about 30 pack-years; cause under evaluation with spirometry and a pulmonology consultationresolvedconfirmed R06.09S — Synthetic presenting problem anchored to his documented emphysema; superseded when spirometry at the consultation confirmed COPD.
Chronic obstructive pulmonary disease, GOLD grade 2 (post-bronchodilator FEV1/FVC 0.58, FEV1 61% predicted by the race-neutral GLI Global equations), GOLD group B (CAT 18, mMRC 2, no exacerbation in the past year); alpha-1 antitrypsin normal; blood eosinophils 0.08 x 10^3/uL; synthetic modern diagnosis linked to his documented emphysemaactiveconfirmed J44.9S — Synthetic modern diagnosis made at the consultation, anchored to his documented emphysema; its onset and course in the modern episode are synthetic.
Former cigarette smoker, about 30 pack-years, stopped eleven years ago on his own; no use sinceactiveconfirmed Z87.891S — Synthetic smoking history: whether he smoked is not documented in the sources read, so the history is synthetic and labeled as such.
Hyperlipidemia: LDL 148 mg/dL, HDL 44 and triglycerides 160 at intake; estimated 10-year cardiovascular risk about 18 percent; atorvastatin started by shared decisionactiveconfirmed E78.5S — Synthetic cardiovascular risk factor anchored to his documented heart trouble; not a claim about his real lipids.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySpirometry: post-bronchodilator FEV1/FVC and FEV1 % predicted (race-neutral GLI Global)At diagnosis, then at least yearly or with a clear changeCompleted todayFEV1 1.92 L before and 2.02 L after albuterol; FVC 3.48 L; FEV1/FVC 0.58; FEV1 61% predicted by GLI Global: obstruction, GOLD grade 2
ExaminationPulse oximetry at restEvery visitCompleted today94 percent on room air, read with the knowledge that oximetry can overestimate saturation in darker skin
LaboratoryArterial blood gasWhen saturation is 92 percent or less, for oxygen assessment, or when oximetry may be unreliableCompleted todayDone because his oximetry may overstate his oxygen level: pH 7.42, PaCO2 40, PaO2 70 mm Hg
SurveySymptoms: CAT and mMRC dyspnea scaleEvery visitCompleted todayCAT 18; mMRC 2 (no LOINC survey code; recorded in the note)
SurveyExacerbations in the past 12 months (moderate and severe) and GOLD groupEvery visitCompleted todayNone in the past year; GOLD group B
Self-managementSmoking status and cessation supportEvery visitCompleted todayFormer smoker, about 30 pack-years, stopped eleven years ago
ExaminationBMI and nutritionEvery visitCompleted todayBMI 22.6; weight steady
LaboratoryBlood eosinophil countAt baseline and when an inhaled corticosteroid is consideredUp to date0.08 x 10^3/uL at intake: argues against an inhaled corticosteroid
LaboratoryAlpha-1 antitrypsinOnce, at diagnosisUp to date142 mg/dL at intake, normal
Medication safetyInhaler technique, adherence and side effects (dry mouth, urinary retention)Every visitCompleted todaySpacer technique correct; dry powder inhaler taught today with a placebo device
ExaminationECG and cardiovascular riskAt baseline; reassess after exacerbationsUp to dateECG normal and NT-proBNP 92 pg/mL at intake
Self-managementVaccines: influenza, pneumococcal, RSV, COVID-19, Tdap, zosterYearly reviewCompleted todayPCV20 and Tdap at intake; influenza, RSV and COVID-19 due in the autumn; zoster to be given then
ImagingLow-dose CT lung cancer screeningYearly at 50 to 80 with 20 or more pack-years, while within fifteen years of quittingOrderedEligible (73, about 30 pack-years, stopped eleven years ago); chose screening after shared decision-making; booked in one week
ReferralPulmonary rehabilitationOffer when mMRC is 2 or more, or CAT 10 or more; within three weeks of a hospital discharge for an exacerbationReferredmMRC 2 and CAT 18; program twice a week from the second week of August; a church volunteer will drive him
ExaminationSix-minute walk testAt rehabilitation entry and exit, and for oxygen assessmentCompleted today360 m on room air; lowest saturation 90 percent
ExaminationLong-term oxygen assessmentWhen resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia) or saturation 88 percent or less, confirmed twiceNot indicatedPaO2 70 mm Hg at rest and lowest walking saturation 90 percent: no long-term or ambulatory oxygen (moderate desaturation, LOTT)
Self-managementWritten and spoken COPD action planAt diagnosis, reviewed after each exacerbationCompleted todayExplained aloud and given in writing: daily inhaler, when to use the reliever, call the clinic the same day for more breathlessness or a change in sputum, call 911 for breathlessness at rest, chest pain or confusion
Medication safetyStatin safety: muscle symptomsEvery visitCompleted todayNo muscle aches
ReferralPulmonology consultationAt diagnosisCompleted todaySeen by Dr. Lindqvist-Bello today

Goal progress:

Guideline basis: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023); CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020); A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016); Racial Bias in Pulse Oximetry Measurement (2020); Lung Cancer: Screening (2021); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026)

Follow-up: Start the new inhaler tomorrow morning. Low-dose CT in one week. Rehabilitation from the second week of August. Eight-week review with a lipid panel. Next scheduled visit 1979-09-08: eight-week review: symptoms on the new inhaler, technique, rehabilitation, the screening CT and the lipid response. [S]